Bank of America Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $315.00

United Therapeutics (NASDAQ:UTHR) had its price objective cut by Bank of America from $321.00 to $315.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock.

Other research analysts also recently issued reports about the company. Cantor Fitzgerald assumed coverage on United Therapeutics in a research report on Monday, June 2nd. They set an “overweight” rating and a $405.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. Morgan Stanley raised their price target on United Therapeutics from $346.00 to $348.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 1st. Wells Fargo & Company reiterated an “equal weight” rating and issued a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Finally, JPMorgan Chase & Co. reduced their target price on United Therapeutics from $355.00 to $350.00 and set an “overweight” rating on the stock in a research note on Thursday, May 1st. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $393.08.

United Therapeutics Trading Down 1.0%

UTHR opened at $283.35 on Wednesday. The firm’s 50 day simple moving average is $300.50 and its two-hundred day simple moving average is $330.86. United Therapeutics has a 1-year low of $266.98 and a 1-year high of $417.82. The company has a market capitalization of $12.78 billion, a PE ratio of 12.44, a PEG ratio of 0.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. During the same period in the prior year, the firm posted $6.17 EPS. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. Equities analysts forecast that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, Director Tommy G. Thompson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the sale, the director now owns 8,480 shares in the company, valued at $2,703,424. This represents a 22.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James Edgemond sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the sale, the chief financial officer now owns 8,118 shares in the company, valued at approximately $2,641,353.66. This represents a 59.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,500 shares of company stock worth $20,828,390 over the last quarter. Insiders own 10.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Signaturefd LLC raised its stake in shares of United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock worth $234,000 after buying an additional 30 shares during the period. Parallel Advisors LLC raised its stake in shares of United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock worth $385,000 after buying an additional 30 shares during the period. Anchor Investment Management LLC raised its stake in shares of United Therapeutics by 12.0% during the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock worth $99,000 after buying an additional 30 shares during the period. Great Lakes Advisors LLC increased its position in shares of United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock worth $697,000 after purchasing an additional 31 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund increased its position in shares of United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after purchasing an additional 33 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.